A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.
Also called NCT05706506
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 152 participants
- Sponsor
- Registry
-
NCT05706506 -
2022-002708-18
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT05706506. Allocation not applicable; no masking; primary purpose treatment. Start 2023-03-08 (actual); primary completion 2023-10-31 (actual). Results posted on 2024-12-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
- Condition
- Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Tirzepatide
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05706506- Content hash
6be8f237d0fa8a011b7c08d3840f8ae511a6dcda92ba501e819c4716d98159ac